|
1
|
Eshraghian A, Kamyab AA and Yoon SK:
Pharmacological treatment for hepatopulmonary syndrome. Biomed Res
Int. 2013:6701392013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Polavarapu N and Tripathi D: Liver in
cardiopulmonary disease. Best Pract Res Clin Gastroenterol.
27:497–512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grace JA and Angus PW: Hepatopulmonary
syndrome: Update on recent advances in pathophysiology,
investigation and treatment. J Gastroenterol Hepatol. 28:213–219.
2013. View Article : Google Scholar
|
|
4
|
Zhang J and Fallon MB: Hepatopulmonary
syndrome: Update on pathogenesis and clinical features. Nat Rev
Gastroenterol Hepatol. 9:539–549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sussman NL, Kochar R and Fallon MB:
Pulmonary complications in cirrhosis. Curr Opin Organ Transplant.
16:281–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang ZJ and Yang CQ: Progress in
investigating the pathogenesis of hepatopulmonary syndrome.
Hepatobiliary Pancreat Dis Int. 9:355–360. 2010.PubMed/NCBI
|
|
7
|
Valenti A and Caimi G: Physiopathological,
clinical and therapeutic aspects of hepatopulmonary syndrome. Clin
Ter. 161:e123–e128. 2010.PubMed/NCBI
|
|
8
|
Macêdo LG and Lopes EP: Hepatopulmonary
syndrome: An update. Sao Paulo Med J. 127:223–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ho V: Current concepts in the management
of hepatopulmonary syndrome. Vasc Health Risk Manag. 4:1035–1041.
2008.
|
|
10
|
Rodríguez-Roisin R and Krowka MJ:
Hepatopulmonary syndrome-a liver-induced lung vascular disorder. N
Engl J Med. 358:2378–2387. 2008. View Article : Google Scholar
|
|
11
|
Varghese J, Ilias-basha H, Dhanasekaran R,
Singh S and Venkataraman J: Hepatopulmonary syndrome-past to
present. Ann Hepatol. 6:135–142. 2007.PubMed/NCBI
|
|
12
|
Kartha RV and Subramanian S: Competing
endogenous RNAs (ceRNAs): New entrants to the intricacies of gene
regulation. Front Genet. 5:82014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Banno K, Iida M, Yanokura M, Kisu I, Iwata
T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer:
OncomiRs and tumor suppressor miRs in diagnosis and treatment.
Scientific World Journal. 2014:1780752014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang Q, Bournzou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/STAT3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang GX, Zhong XY, Cui YF, et al:
IL-6/STAT3/TFF3 signaling regulates human biliary epithelial cell
migration and wound healing in vitro. Mol Biol Rep. 37:3813–3818.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang G, Qian P, Jackson FR, Qian G and Wu
G: Sequential activation of JAKs, STATs and xanthine
dehydrogenase/oxidase by hypoxia in lung microvascular endothelial
cells. Int J Biochem Cell Biol. 40:461–470. 2008. View Article : Google Scholar
|
|
17
|
Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang
QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,
2/STAT3 signaling induces apoptosis, cell cycle arrest and reduces
tumor cell invasion in colorectal cancer cells. Neoplasia.
10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Januma N, Shima H, Nakamura K and Kikuchi
K: Protein tyrosine phosphatase epsilonC selectively inhibits
interleukin-6- and IL-10- induced JAK-STAT signaling. Blood.
98:3030–3034. 2001. View Article : Google Scholar
|
|
19
|
Takeda K and Akim S: Stat family of
transcription factors in cytokine-mediated biological responses.
Cytokine Growth Factor Rev. 11:199–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuczkowski J, Sakowicz-Burkiewica M,
Izycka-Swieszewska E, Mikaszewski B and Pawełczyk T: Expression of
tumor necrosis factor-α, interleukin-1α, interleukin-6 and
interleukin-10 in chronic otitis media with bone osteolysis. ORL J
Otorhinolaryngol Relat Spec. 73:93–99. 2011. View Article : Google Scholar
|
|
21
|
Nason R, Jung JY and Chole RA:
Lipopolysaccharide-induced osteoclastogenesis from mononuclear
precursors: A mechanism for osteolysis in chronic otitis. J Assoc
Res Otolaryngol. 10:151–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo F, Cogdell D, Hu L, Yang D, Sood AK,
Xue F and Zhang W: miR-101 suppresses the epithelial-to-mesenchymal
transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol
Rep. 31:2021–2028. 2014.PubMed/NCBI
|
|
23
|
Lin X, Guan H, Li H, Liu L, Liu J, Wei G
and Zhang W: miR-101 inhibits cell proliferation by targeting Rac1
in papillary thyroid carcinoma. Biomed Rep. 2:122–126.
2014.PubMed/NCBI
|
|
24
|
Barbato C, Pezzola S, Caggiano C,
Antonelli M, Frisone P, Ciotti MT and Ruberti F: A lentiviral
sponge for miR-101 regulates RanBP9 expression and amyloid
precursor protein metabolism in hippocampal neurons. Front Cell
Neurosci. 8:372014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin C, Huang F, Zhang YJ, Tuokan T and
Kuerban G: Roles of MiR-101 and its target gene Cox-2 in early
diagnosis of cervical cancer in Uygur women. Asian Pac J Cancer
Prev. 15:45–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Y, Xiang W, Wang M, Huang T, Xiao X,
Wang L, Tao D, Dong L, Zeng F and Jiang G: Methyl jasmonate
sensitizes human bladder cancer cells to gambogic acid-induced
apoptosis through downregulation of EZH2 expression by miR-101. Br
J Pharmacol. 171:618–635. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiaoping L, Zhibin Y, Wenjuan L, Zeyou W,
Gang X, Zhaohui L, Ying Z, Minghua W and Guiyuan L: CPEB1, a
histone-modified hypomethylated gene, is regulated by miR-101 and
involved in cell senescence in glioma. Cell Death Dis. 4:e6752013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang R, Wang HB, Hao CJ, Cui Y, Han XC, Hu
Y, Li FF, Xia HF and Ma X: MiR-101 is involved in human breast
carcinogenesis by targeting Stathmin1. PLoS One. 7:e461732012.
View Article : Google Scholar : PubMed/NCBI
|
